NCT05116254View on ClinicalTrials.gov

Sarcomas and DDR-Inhibition; a Combined Modality Study

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

March 1, 2026

Study Completion Date

July 1, 2028

Conditions
Soft Tissue Sarcoma Adult
Interventions
COMBINATION_PRODUCT

AZD1390 + radiotherapy

AZD1390 combined with preoperative radiotherapy

COMBINATION_PRODUCT

AZD1390 + durvlaumab + radiotherapy

AZD1390 combined with durvalumab and preoperative radiotherapy

Trial Locations (1)

1066CX

RECRUITING

Antoni van Leeuwenhoek, Amsterdam

All Listed Sponsors
collaborator

Leiden University Medical Center

OTHER

collaborator

University Medical Center Nijmegen

OTHER

lead

The Netherlands Cancer Institute

OTHER